Literature DB >> 33737688

Evaluation of moxifloxacin-induced cytotoxicity on human corneal endothelial cells.

Joo-Hee Park1,2, Martha Kim1,3, Roy S Chuck4, Choul Yong Park5,6.   

Abstract

Moxifloxacin hydrochloride (MXF) is widely used for the prevention of bacterial endophthalmitis after intraocular surgeries. However, the safety issue of intracameral injection of MXF for human corneal endothelial cells (HCECs) is still debatable. In this study, we investigated concentration-dependent cytotoxicity (0.05-1 mg/ml) of MXF for immortalized HCECs (B4G12 cell) and the underlying mechanism. Reactive oxygen generation (ROS) and cell viability after MXF exposure was measured. Flow cytometric analysis and TUNEL assay was used to detect apoptotic HCECs after MXF exposure. Ultrastructure of damaged HCECs by MXF was imaged by transmission electron microscope. Western blot analysis and caspase 2, 3 and 8 analysis were used to reveal the underlying mechanism of MXF induced damage in HCECs. We found that MXF induced dose-dependent cytotoxicity in HCECs. MXF exposure increased ROS generation and induced autophagy in HCECs. Increased LDH release represented the cellular membrane damage by MXF. In addition, caspases activation, Bax/Bcl-xL-dependent apoptosis pathway and apoptosis inducing factor nuclear translocation were all involved in MXF induced HCECs' damage, especially after exposure to high dose of MXF (0.5 and 1.0 mg/ml). These findings suggest that MXF toxicity on HCECs should be thoroughly considered by ophthalmologists when intracameral injection of MXF is planned.

Entities:  

Year:  2021        PMID: 33737688     DOI: 10.1038/s41598-021-85834-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  30 in total

1.  Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.

Authors:  Stephen S Lane; Robert H Osher; Samuel Masket; Shaleen Belani
Journal:  J Cataract Refract Surg       Date:  2008-09       Impact factor: 3.351

2.  Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro.

Authors:  Tomoko Haruki; Dai Miyazaki; Kazuki Matsuura; Yuki Terasaka; Yumiko Noguchi; Yoshitsugu Inoue; Satoru Yamagami
Journal:  J Cataract Refract Surg       Date:  2014-09-26       Impact factor: 3.351

3.  Reply.

Authors:  Mathias V Melega; Monica Alves; Rodrigo Pessoa Cavalcanti Lira; Iuri Cardoso da Silva; Bruna Gil Ferreira; Hermano L G Assis Filho; Fernando Rodrigo Pedreira Chaves; Alexandre A F Martini; Livia Maria Dias Freire; Roberto Dos Reis; Carlos Eduardo Leite Arieta
Journal:  J Cataract Refract Surg       Date:  2019-06       Impact factor: 3.351

4.  Comparison of the influence of intracameral gentamicin, gatifloxacin, and moxifloxacin on the corneal endothelium in a rabbit model.

Authors:  Shinichiro Kobayakawa; Yoshimune Hiratsuka; Yasuo Watabe; Akira Murakami; Tetsuo Tochikubo
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

5.  The effect of moxifloxacin on the normal human cornea.

Authors:  Kendall E Donaldson; Fabiana B Marangon; Lauren Schatz; Anna S Venkatraman; Eduardo C Alfonso
Journal:  Curr Med Res Opin       Date:  2006-10       Impact factor: 2.580

6.  Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.

Authors:  Cesar Ramon G Espiritu; Victor L Caparas; Joanne G Bolinao
Journal:  J Cataract Refract Surg       Date:  2007-01       Impact factor: 3.351

7.  Does moxifloxacin alter oxidant status in the cornea? An experimental study.

Authors:  Ali Akal; Turgay Ulas; Tugba Goncu; Muhammet Emin Guldur; Sezen Kocarslan; Abdullah Taskin; Emin Savik; Ufuk Ozkan; Emel Yigit Karakas; Mete Koksal; Nurten Aksoy
Journal:  Cutan Ocul Toxicol       Date:  2014-06-25       Impact factor: 1.820

8.  Toxicity of Intracameral Injection of Fourth-Generation Fluoroquinolones on the Corneal Endothelium.

Authors:  Francisco Bandeira E Silva; Linda Christian Carrijo-Carvalho; Anderson Teixeira; Denise de Freitas; Fabio Ramos de Souza Carvalho
Journal:  Cornea       Date:  2016-12       Impact factor: 2.651

9.  Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model.

Authors:  Leyla Asena; Yonca A Akova; Mustafa T Goktaş; Atilla Bozkurt; Umit Yaşar; Gülten Karabay; Ebru Demiralay
Journal:  Curr Eye Res       Date:  2013-02-01       Impact factor: 2.424

10.  Intracameral moxifloxacin: in vitro safety on human ocular cells.

Authors:  Marcus Kernt; Aljoscha S Neubauer; Raffael G Liegl; Carl A Lackerbauer; Kirsten H Eibl; Claudia S Alge; Michael W Ulbig; Anselm Kampik A
Journal:  Cornea       Date:  2009-06       Impact factor: 2.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.